Kim Janda - Sep 13, 2021 Form 4 Insider Report for Sorrento Therapeutics, Inc. (SRNEQ)

Role
Director
Signature
/s/ Henry Ji, Ph.D., as Attorney-in-Fact
Stock symbol
SRNEQ
Transactions as of
Sep 13, 2021
Transactions value $
-$36,285
Form type
4
Date filed
9/14/2021, 05:00 PM
Previous filing
Aug 30, 2021
Next filing
Sep 28, 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRNEQ Common Stock Options Exercise $28K +8K +266.67% $3.50 11K Sep 13, 2021 Direct F1
transaction SRNEQ Common Stock Sale -$64.3K -8K -72.73% $8.04 3K Sep 13, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRNEQ Non-qualified stock option Options Exercise $0 -8K -100% $0.00* 0 Sep 13, 2021 Common Stock 8K $3.50 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.84 to $8.23, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F3 25% of the shares subject to the option vested on September 28, 2012, and 1/48th of the shares subject to the option vested monthly thereafter.